Characteristic | n = 91 |
---|---|
Baseline (end of treatment) | |
 Age, years | 35.7 ± 7.9 |
 Sex (Male: Female) | 75:16 |
 First-line NA therapy a | 39 (42%) |
 Therapy duration, years | 56.7 ± 26.2 |
 Consolidation therapy duration, months | 28 (18–46) |
 ALT level, × ULN | 0.5 (0.4–0.7) |
ALT elevation, n (%) | |
 < ULN | 78 (86%) |
 ULN-2 × ULN | 12 (13%) |
 HBV DNA level, log10 IU/ml | UD |
 HBsAg level, log10 IU/ml | 2.9 (2.3–3.3) |
 < 100 IU/ml | 20 (22%) |
 100–1000 IU/ml | 31 (34%) |
 > 1000 IU/ml | 40 (44%) |
Start of treatment | |
 HBeAg status (Positive: Negative) | 61:30 |
 ALT elevation ×ULN | 5.33 ± 4.29 |
 HBV DNA log10 IU/ml | 6.20 ± 1.41 |